Hikmet Al-Hiti

TL;DR: Bosentan treatment could be beneficial for patients with WHO FC II pulmonary arterial hypertension.

TL;DR: In combined post- and pre-capillary PH patients, macitentan was associated with increased incidence of significant fluid retention versus placebo, and Macitentan-treated patients were quantitatively more likely to experience significant fluid storage versus placebo.

TL;DR: In vivo evidence that phosphodiesterase 5A inhibition restores sensitivity of pulmonary vasculature to endogenous cGMP-dependent vasodilators is provided, which is reversible by the administration of sildenafil.

TL;DR: This registry from the Czech Republic highlights that diagnosis of PAH is frequently made late in the disease continuum when patients have significant functional impairment, and the prevalence, incidence and survival of patients with PAH from a national representative registry is described.

TL;DR: The majority of patients exposed to long-term bosentan maintained or improved their functional class and survival and factors prognostic of survival, and PAH associated with connective tissue disease were associated with a higher risk of death.